The US Food and Drug Administration has a dozen user fee goal dates for pending applications coming up in June, according to the Pink Sheet’s US FDA Performance Tracker.
US FDA Approval Actions To Watch Out For In June
User fee goal date calendar for June includes AMAG’s female sexual dysfunction drug Vyleesi, new indications for Sanofi/Regeneron’s Dupixent in rhinosinusitis and Merck’s Zerbaxa in nosocomial pneumonia.
